Specifically, oridonin inhibits BCR-ABL activity in leukemia cells by binding to the cysteine-153 residue within the HSF1 domain, leading to increased expression of HSP70 and ubiquitin proteins that promote BCR-ABL degradation. The gene discussed is ABL1; the disease is leukemia.